BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 16112026)

  • 1. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Poland GA
    Vaccine; 2007 Apr; 25(16):3090-100. PubMed ID: 17280755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
    Hum Immunol; 2004 Dec; 65(12):1506-15. PubMed ID: 15603879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
    J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
    Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG
    Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
    Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
    Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
    In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine.
    St Sauver JL; Ovsyannikova IG; Jacobson RM; Jacobsen SJ; Vierkant RA; Schaid DJ; Pankratz VS; Green EM; Poland GA
    J Infect Dis; 2002 Jun; 185(11):1545-9. PubMed ID: 12023759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.